GMDx has developed a world-class AI technology to analyze a person’s genomic sequence and determine an individual’s immune fitness which enables a personalized cancer treatment plan.

 

The Innate Immune Fitness (IIF) profile consistently reveals the significant contribution of deaminase signatures to patient outcomes.

 

GMDx understands the genetic links between inflammation, immunity and disease.

​

GMDx has multiple scientifically published, patented genomic discoveries to develop tests in cancer for treatment selection, disease progression and early detection.

 

The GMDx enabling platform utilizes an industry-leading framework built on the Oracle Autonomous Cloud. The platform is readily accessible to GMDx partners globally. The Oracle partnership ensures compliance with all privacy and security requirements.